Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | completed | Phase 3 | 1,334 | TakedaINDUSTRY | 21 | Feb 27, 2026 | clinicaltrials |
| NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | completed | Phase 3 | 125 | Gamida Cell ltdINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) |
| completed |
| Phase 3 |
| 304 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 0 |
| Feb 18, 2026 |
| clinicaltrials |
| NCT05804032 | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 514 | University of Heidelberg Medical CenterOTHER | 2 | Feb 18, 2026 | clinicaltrials |
| NCT04214444 | Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab(EVAPOR) | completed | Phase 3 | 26 | University Hospital, ToursOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT01358747 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL(AHL 2011) | completed | Phase 3 | — | Centre Hospitalier Universitaire DijonOTHER | 2 | Feb 9, 2026 | clinicaltrials |
| NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | completed | Phase 3 | 482 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 10 | Feb 9, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT03594149 | Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients(AZABAC) | completed | Phase 3 | 60 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | completed | Phase 3 | 1,023 | Goethe UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | completed | Phase 3 | 371 | Astellas Pharma Global Development, Inc.INDUSTRY | 14 | Dec 4, 2025 | clinicaltrials |
| NCT03808805 | Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms(APHYPAP) | completed | Phase 3 | 63 | University Hospital, BrestOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04620369 | Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy | completed | Phase 3 | 106 | Mayo ClinicOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma(ZUMA-7) | completed | Phase 3 | 359 | Kite, A Gilead CompanyINDUSTRY | 14 | Dec 1, 2025 | clinicaltrials |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 445 | Hoffmann-La RocheINDUSTRY | 21 | Nov 6, 2025 | clinicaltrials |
| NCT03136445 | TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia(TREATT) | completed | Phase 3 | 616 | NHS Blood and TransplantOTHER_GOV | 2 | Oct 28, 2025 | clinicaltrials |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 737 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 20, 2025 | clinicaltrials |
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT01241708 | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma((Mel/MelVel)) | completed | Phase 3 | 148 | Hackensack Meridian HealthOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 498 | Janssen Research & Development, LLCINDUSTRY | 15 | Aug 29, 2025 | clinicaltrials |
| NCT00278408 | Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 3 | 700 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 4 | Aug 26, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT02066454 | Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs(MYELAXAT) | completed | Phase 3 | 108 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03159897 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | completed | Phase 3 | 500 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT00049595 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma | completed | Phase 3 | 552 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 5, 2025 | clinicaltrials |
| NCT03575351 | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas(TRANSFORM) | completed | Phase 3 | 184 | CelgeneINDUSTRY | 12 | Aug 3, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission(QUAZAR AML-001) | completed | Phase 3 | 472 | CelgeneINDUSTRY | 23 | Jul 8, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT03941860 | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | completed | Phase 3 | 1 | National Cancer Institute (NCI)NIH | 2 | May 23, 2025 | clinicaltrials |
| NCT02577406 | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation(IDHENTIFY) | completed | Phase 3 | 319 | CelgeneINDUSTRY | 18 | May 18, 2025 | clinicaltrials |
| NCT03080883 | Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy | completed | Phase 3 | 370 | Academic and Community Cancer Research UnitedOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | CelgeneINDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 569 | Janssen Research & Development, LLCINDUSTRY | 18 | May 1, 2025 | clinicaltrials |
| NCT03277105 | A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 522 | Janssen Research & Development, LLCINDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT01303887 | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients(PACIFICO) | completed | Phase 3 | 680 | University of LiverpoolOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02541383 | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma(Cassiopeia) | completed | Phase 3 | 1,085 | Intergroupe Francophone du MyelomeNETWORK | 3 | Apr 13, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 27, 2026source: clinicaltrials